COVID-19 MESSAGE FROM BMMSA

Our first priority is the health, wellness and safety of everyone who walks through our doors.

Bryn Mawr Medical Specialists Association is open for medically necessary office visits and procedures only. BMMSA as a corporation is taking all necessary precautions and following public health safety guidelines in regards to the COVID-19 pandemic.

TeleMedicine appointments are now available. Please contact your physicians office for eligibility, additional information, and with any concerns or questions.

As per order of the Commonwealth of Pennsylvania, any person entering our office building is required to wear a face mask at all times. Patients will not be permitted to enter the building without a face mask.

All patients should expect to be phone screened by Bryn Mawr Medical Specialists Association staff for COVID-19 symptoms or exposures prior to their appointment and again upon arrival. Patients should also expect to be temperature screened upon arrival in the office.

If your answer to any of the following questions is “Yes”, we ask that you call to reschedule your appointment.

In the past 14 days, have you developed any fever, cough or shortness of breath?
In the past 14 days, have you developed any of the following new symptoms?

  • Body aches or muscle pains?
  • Chills or repeated shaking with chills?
  • Headache?
  • Sore throat?
  • New loss of taste or of smell?
  • Have you, or anyone you have close contact with, been recently referred for COVID-19 testing?

In the past 14 days, have you traveled outside of PA? If “Yes”, please call the office to notify us of travel BEFORE your appointment. Patients recently returning from travel restricted states or countries will be asked to reschedule their appointment.

For the safety of our staff and other patients, patient family members or companions are not permitted at this time to accompany patients to their appointments (unless medically necessary or the patient is a minor). Bryn Mawr Medical Specialists Association respectfully asks family members or companions to wait outside or safely in their vehicle.

We encourage all of our patients to visit the CDC website and Main Line Health COVID-19 Response website to read more about everyday preventative measures and for the most up to date guidance regarding the Coronavirus (COVID-19). If you are concerned that you may have the Coronavirus (COVID-19), please contact your local Health Departments.

If you have any questions regarding our policy and your appointment, please call your doctor’s office.

Sameer Gupta, M.D., M.P.H.

Hematology/Oncology

Specialties

  • Medical Oncology

    Board Certified in 2011

  • Hematology

    Board Certified in 2011

  • Internal Medicine

    Board Certified in 2011

Location

Bryn Mawr Medical Arts Pavilion
825 Old Lancaster Road
Suite 440
Bryn Mawr, PA 19010
Phone: (610) 525-4511
Fax: (610) 525-8561

Education & Training

Medical School

Maulana Azad Medical College, New Delhi, India

Masters

University of Alabama at Birmingham

Residency

  • State University of New York at Buffalo
  • All India Institute of Medical Sciences, New Delhi, India

Fellowships

  • Fox Chase Cancer Center
  • Temple University Hospital

Affiliations

  • Bryn Mawr Hospital
  • Paoli Hospital
  • Lankenau Hospital

Clinical/Dept Titles

Clinical Assistant Professor

Jefferson Medical College

Attending Physician, Hematology-Oncology

Bryn Mawr Hospital

Professional Advisory Boards

  1. UNITE for HER
  2. BreastCancer.Org

Honors & Awards

Recent Clinical Studies Published

  • Ali SA, Gupta S, Sehgal R, Vogel V. Survival outcomes in pregnancy associated breast cancer: a retrospective case control study. Breast J. 2012 Mar;18(2):139-44.(PMID: 22356297)
  • Gupta S, Engstrom PF and Cohen SJ. Emerging Therapies for Advanced Gastroenteropancreatic Neuroendocrine Tumors: Invited Review, Clinical Colorectal Cancer, August 1, 2011. (PMID: 21813338)
  • Gupta S and Goldstein L. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735. Invited Commentary, Breast Diseases: A Year Book Quarterly. Vol. 21 No. 3, October 2010
  • Aggarwal C, Gupta S, Hahn T et al. Human leukocyte antigen DR4 is associated with inferior progression-free survival following allogeneic hematopoietic stem cell transplantation for lymphoid malignancies. Leukemia and Lymphoma, 2008 Aug; 49(8):1494-500. (PMID: 18766961)
  • Gupta S, Almyroudis N, Battiwala M et al. Successful treatment of disseminated fusariosis with posaconazole during neutropenia and subsequent allogeneic hematopoietic stem cell transplantation. Transplant Infectious Disease, 2007 Jun; 9(2):156-60. (PMID: 17462004)
  • Gupta S, Silliman C and Trump DL. Docetaxel Induced Meibomian Duct Inflammation and Blockage Leading to Chalazion Formation. Prostate Cancer and Prostatic Diseases, 2007; 10: 396-397. (PMID: 17404582)
  • Aggarwal C and Gupta S. Case 24-2006: A Woman with Hypotension after an Overdose of Amlodipine. New England Journal of Medicine, 2006: 355; 1936; author reply 1937-8. (PMID: 17079775)
  • Aggarwal C, Gupta S, Vaughan WP et al. Improved Outcomes in Intermediate and High Risk Aggressive Non-Hodgkin’s Lymphoma after Autologous Hematopoietic Stem Cell Transplantation Substituting Intravenous for Oral Busulfan in a Busulfan, Cyclophosphamide and Etoposide Preparative Regimen. Biology of Blood and Marrow Transplantation, 2006, 12:770-777. (PMID: 16785066)
  • Gupta R and Gupta S. Urticaria due to inhalant allergens. Indian J Dermatol Venereol Leprol 2003; 69:429. (PMID: 17642963)
  • Gupta R and Gupta S. Fever due to levamisole. Indian J Dermatol Venereol Leprol 2003; 69:237-238. (PMID: 17642899)

Current Memberships & Activities

  • American Association for Cancer Research
  • American Society of Clinical Oncology
  • American Society of Hematology

Hematology/Oncology

Browse available departments: